Indikation for behandling med NeoRecormon af nefrosklerotiske patienter, som endnu ikke får dialyse, skal fastlægges individuelt, da en mulig acceleration af progredierende nyresvigt ikke kan udelukkes.
The indication for treatment with NeoRecormon of nephrosclerotic patients not yet undergoing dialysis should be defined individually, as a possible acceleration of progression of renal failure cannot be ruled out with certainty.